

REMARKS/ARGUMENTS

In response to the Office Action of April 25, 2006, and subsequent to an interview granted to Applicants' representative Ferris H. Lander on August 16, 2006, Applicant requests re-examination and reconsideration of this application for patent pursuant to 35 U.S.C. 132.

During the interview various modifications to the claims were discussed which, if inserted therein, would obviate any inconsistencies in language, and further render the claims in a form appropriate for rejoinder.

Basis for the binding of human colon, ovarian, lung and breast can be found in the original disclosure *inter alia* at pages 12, 13, 27, and 30.


Additionally, with respect to the questions of enablement relating to the Wands factors, as it pertains to the ability of the antibody and antigen binding fragments thereof to mediate cytotoxicity, it was agreed to submit an affidavit of the inventor, showing demonstrative evidence of this utility.

Accordingly, the above amendments and instant submission of a Declaration under 37 CFR § 1.132, are deemed to place the application in condition for allowance.

SUMMARY

In light of the foregoing remarks and amendment to the claims, it is respectfully submitted that the Examiner will now find the claims of the application allowable. Favorable reconsideration of the application is courteously requested.

Respectfully submitted,



Ferris H. Lander  
Registration # 43,377

McHale & Slavin, P.A.  
2855 PGA Boulevard  
Palm Beach Gardens, FL 33410  
(561) 625-6575 (Voice)  
(561) 625-6572 (Fax)

\\Na2\server\CLIENT FILES\2000-2099\2056 - Arius Research, Inc\2056\_000020 -  
PAT\Amendments\2056.020 Supplemental Resp OA 4-25-06 AS FILED.upd